Istavel 50 Mg (Sitagliptin)

Product Overview

Istavel 50 Mg is a prescription oral antidiabetic medication manufactured by Sun Pharmaceutical Industries Ltd. Each strip contains ten film‑coated tablets, each delivering a precise dose of 50 mg of sitagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor that has received regulatory approval for the management of Type 2 diabetes mellitus. The product is formulated for convenient once‑daily administration and is marketed in pack sizes of 100, 200, and 300 tablets, allowing patients and healthcare providers to select the most appropriate supply for long‑term therapy. Istavel is indicated as an adjunct to a healthy diet and regular physical activity to improve glycemic control in adults with Type 2 diabetes who have not achieved adequate glucose levels with lifestyle modification alone.

What is Istavel 50 Mg

Istavel 50 Mg contains sitagliptin phosphate, the active pharmaceutical ingredient that selectively blocks the DPP‑4 enzyme. By inhibiting this enzyme, sitagliptin prolongs the activity of incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin release from pancreatic β‑cells in a glucose‑dependent manner and suppress hepatic glucagon secretion, resulting in a balanced reduction of both fasting and post‑prandial blood glucose concentrations. The drug does not cause weight gain and has a low propensity for hypoglycemia when used as monotherapy, making it a valuable option in the pharmacologic armamentarium for Type 2 diabetes.

Uses and Benefits

Clinically, Istavel 50 Mg offers several therapeutic advantages for patients with Type 2 diabetes:

• Improved glycemic control reflected by reductions in HbA1c ranging from 0.5% to 1.5% when used in combination with diet, exercise, or other antidiabetic agents.
• Once‑daily dosing simplifies the medication regimen, which can enhance patient adherence and long‑term persistence.
• A favorable safety profile with the most common adverse events being mild and transient, such as nasopharyngitis and urinary tract infections.
• Reduced risk of hypoglycemia compared with sulfonylureas or insulin when prescribed alone, especially in older adults or those with renal impairment.
• Compatibility with a wide range of concomitant diabetes medications, allowing flexible combination therapy tailored to individual patient needs.

These benefits contribute to better overall glucose control, which can lower the likelihood of microvascular and macrovascular complications associated with diabetes, including retinopathy, nephropathy, and cardiovascular disease.

How It Works

The mechanism of action of sitagliptin centers on the preservation of incretin hormones that are normally degraded by the DPP‑4 enzyme. When DPP‑4 activity is inhibited, circulating levels of GLP‑1 and GIP increase, leading to enhanced glucose‑dependent insulin secretion from pancreatic β‑cells and suppression of glucagon release from α‑cells. This dual effect results in a glucose‑lowering response that is proportional to the elevation of blood glucose, thereby minimizing the risk of excessive hypoglycemia. Additionally, sitagliptin modestly reduces hepatic glucose production, further contributing to improved fasting glucose concentrations. The pharmacodynamic profile of sitagliptin is characterized by a long half‑life of approximately 12.5 hours, supporting once‑daily dosing and steady therapeutic levels throughout the day.

Dosage Guidelines

Therapeutic dosing of Istavel 50 Mg should be individualized based on patient characteristics, concomitant medications, and renal function. The recommended starting dose for most adults is 100 mg once daily, taken with or without food. However, a 50 mg strength is specifically formulated for patients who require dose reduction, such as those with moderate renal impairment (estimated glomerular filtration rate [eGFR] between 30 and 50 mL/min/1.73 m²). In these patients, a once‑daily dose of 50 mg is recommended to avoid accumulation of the drug and its active metabolites. For patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or those undergoing hemodialysis, the dose may need to be adjusted further or administered under close medical supervision. Patients should always follow the dosing instructions provided by their prescribing clinician and should not modify the dose without professional guidance.

Side Effects

Istavel 50 Mg is generally well tolerated, but like all medications, it can be associated with adverse effects. The majority of reported side effects are mild to moderate and resolve spontaneously. Commonly observed adverse reactions include:

• Nasopharyngitis (inflammation of the nasal passages and pharynx).
• Urinary tract infections, which may present with dysuria or frequency.
• Headache, often mild and transient.
• Hypoglycemia when Istavel is co‑administered with sulfonylureas, insulin, or other insulin secretagogues; patients should be educated on recognizing the signs of low blood glucose.
• Pancreatitis, a rare but serious condition characterized by severe abdominal pain radiating to the back, nausea, and vomiting; patients should seek immediate medical attention if these symptoms occur.

Less frequently, patients may experience skin rash, pruritus, or elevated liver enzymes. If any adverse reaction becomes persistent or severe, medical evaluation is recommended.

Warnings and Precautions

Prior to initiating therapy with Istavel 50 Mg, healthcare providers should assess the following warnings and precautions:

• Hypersensitivity reactions: Discontinue the medication if signs of allergic reaction such as rash, pruritus, or angioedema develop.
• Pancreatic considerations: Patients with a history of pancreatitis or pancreatic carcinoma should be monitored closely, as rare cases of pancreatitis have been reported.
• Renal impairment: Dose adjustment is mandatory; the 50 mg strength is intended for patients with moderate renal dysfunction, while lower doses or alternative therapies may be required in severe renal disease.
• Pregnancy and lactation: The safety of sitagliptin during pregnancy and breastfeeding has not been established; use only if the potential maternal benefit justifies the potential fetal risk.
• Drug interactions: Caution is advised when Istavel is used concomitantly with strong CYP3A4 inducers or inhibitors, as well as with other antidiabetic agents that may increase the risk of hypoglycemia.

Healthcare professionals should consult the FDA prescribing information and authoritative clinical guidelines for comprehensive risk assessment.

Frequently Asked Questions

1. What distinguishes Istavel 50 mg from the 100 mg formulation?
Istavel 50 mg is a lower‑dose tablet designed for patients who require a reduced amount of sitagliptin, typically those with moderate renal impairment or specific clinical circumstances that warrant dose titration. The 100 mg tablet is the standard dose prescribed for the majority of adult patients.

2. Can Istavel be prescribed for patients with Type 1 diabetes?
Istavel is approved only for the treatment of Type 2 diabetes mellitus. Its efficacy and safety have not been established in patients with Type 1 diabetes, and it is not recommended for use in this population.

3. How should Istavel tablets be stored?
Store the medication at room temperature, away from excessive heat and moisture. Keep the strip sealed until ready for use, and ensure that the product is kept out of reach of children and pets.

4. Is it safe to combine Istavel with other diabetes medications?
Istavel can be used in combination with metformin, sulfonylureas, or insulin, but dosage adjustments may be necessary to minimize the risk of hypoglycemia. Patients should always consult their healthcare provider before adding or removing any medication from their regimen.

5. Where can I obtain detailed prescribing information?
The complete FDA‑approved prescribing label, including dosing recommendations, contraindications, and safety data, is available through the FDA’s drug label database (FDA) and on reputable medical resources such as the National Institutes of Health (NIH) and MedlinePlus (MedlinePlus). Additional peer‑reviewed studies can be accessed via PubMed.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)